Showing results (91-100 of 223) with videos related to

Sort By:
Pageof 23
The Journal of Urology|September 1, 1988
Phagocytic and natural killer cytotoxic responses of murine transitional cell carcinoma to postsurgical immunochemotherapyJ L Woolley, B H Lau, H C Ruckle, et al.
Techniques in Urology|July 1, 1997
Endoscopic treatment of continent urinary reservoir calculiS A Ramin, M A Beaghler, H C Ruckle, et al.
Urology|May 1, 1999
Perfusion sphincterometry for objective evaluation of postprostatectomy intrinsic sphincter deficiencyB R Bamshad, H R Hadley, H C Ruckle, et al.
The Journal of Urology|January 1, 1996
The effect of finasteride on prostate specific antigen: review of available dataH A Guess, G J Gormley, E Stoner, et al.
The Journal of Urology|January 1, 1994
Measurement of serum prostate specific antigen using IMx prostate specific antigen assayG G Klee, L A Dodge, H Zincke, et al.
Urology|March 1, 1993
Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor gradeE Kleer, J J Larson-Keller, H Zincke, et al.
The Journal of Urology|February 25, 1998
A model for the number of cores per prostate biopsy based on patient age and prostate gland volumeA R Vashi, K J Wojno, B Gillespie, et al.
The Urologic Clinics of North America|November 1, 1993
PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumorsJ E Oesterling, V J Suman, H Zincke, et al.
The Journal of Urology|August 1, 1997
A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancerM J Barry, F J Fowler, L Bin, et al.
Urology|June 1, 1993
Prognostic implications of prostate-specific antigen in patients with locally advanced prostate cancer treated with high energy neutron beam therapy: preliminary resultsK R Saroja, J E Oesterling, F Hendrickson, et al.
Pageof 23